Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
Código da empresaDARE
Nome da EmpresaDare Bioscience Inc
Data de listagemApr 10, 2014
CEOMs. Sabrina Martucci Johnson
Número de funcionários21
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 10
Endereço3655 Nobel Dr Ste 260
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92122-1050
Telefone18589267655
Sitehttps://www.darebioscience.com/
Código da empresaDARE
Data de listagemApr 10, 2014
CEOMs. Sabrina Martucci Johnson
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados